Cytogenomic Profile of Uterine Leiomyoma: In Vivo vs. In Vitro Comparison

We performed a comparative cytogenomic analysis of cultured and uncultured uterine leiomyoma (UL) samples. The experimental approach included karyotyping, aCGH, verification of the detected chromosomal abnormalities by metaphase and interphase FISH, MED12 mutation analysis and telomere measurement by Q-FISH. An abnormal karyotype was detected in 12 out of 32 cultured UL samples. In five karyotypically abnormal ULs, MED12 mutations were found. The chromosomal abnormalities in ULs were present mostly by complex rearrangements, including chromothripsis. In both karyotypically normal and abnormal ULs, telomeres were ~40% shorter than in the corresponding myometrium, being possibly prerequisite to chromosomal rearrangements. The uncultured samples of six karyotypically abnormal ULs were checked for the detected chromosomal abnormalities through interphase FISH with individually designed DNA probe sets. All chromosomal abnormalities detected in cultured ULs were found in corresponding uncultured samples. In all tumors, clonal spectra were present by the karyotypically abnormal cell clone/clones which coexisted with karyotypically normal ones, suggesting that chromosomal abnormalities acted as drivers, rather than triggers, of the neoplastic process. In vitro propagation did not cause any changes in the spectrum of the cell clones, but altered their ratio compared to uncultured sample. The alterations were unique for every UL. Compared to its uncultured counterpart, the frequency of chromosomally abnormal cells in the cultured sample was higher in some ULs and lower in others. To summarize, ULs are characterized by both inter- and intratumor genetic heterogeneity. Regardless of its MED12 status, a tumor may be comprised of clones with and without chromosomal abnormalities. In contrast to the clonal spectrum, which is unique and constant for each UL, the clonal frequency demonstrates up or down shifts under in vitro conditions, most probably determined by the unequal ability of cells with different genetic aberrations to exist outside the body.

[1]  C. Simón,et al.  Molecular and Cellular Insights into the Development of Uterine Fibroids , 2021, International journal of molecular sciences.

[2]  V. Baranov,et al.  Telomere Length in Chromosomally Normal and Abnormal Miscarriages and Ongoing Pregnancies and Its Association with 5-hydroxymethylcytosine Patterns , 2021, International journal of molecular sciences.

[3]  V. Baranov,et al.  Telomere Length in Metaphase Chromosomes of Human Triploid Zygotes , 2021, International journal of molecular sciences.

[4]  Dong Zhang,et al.  ALT Positivity in Human Cancers: Prevalence and Clinical Insights , 2021, Cancers.

[5]  V. Baranov,et al.  Uterine Leiomyomas with an Apparently Normal Karyotype Comprise Minor Heteroploid Subpopulations Differently Represented in vivo and in vitro , 2021, Cytogenetic and Genome Research.

[6]  F. Chibon,et al.  Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond , 2020, Genes, chromosomes & cancer.

[7]  P. Campbell,et al.  APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis , 2020, Nature Genetics.

[8]  O. A. Efimova,et al.  Environmental Epigenetics and Genome Flexibility: Focus on 5-Hydroxymethylcytosine , 2020, International journal of molecular sciences.

[9]  S. As-Sanie,et al.  Epidemiology and management of uterine fibroids , 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  D. Baird,et al.  Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African-Americans. , 2020, American journal of obstetrics and gynecology.

[11]  V. Baranov,et al.  Pathogenomics of Uterine Fibroids Development , 2019, International journal of molecular sciences.

[12]  A. Ciavattini,et al.  Comparison of uterine fibroids’ growth pattern during pregnancy according to fetal sex: an observational study , 2019, Biology of Sex Differences.

[13]  A. Shushan,et al.  Growth pattern of uterine leiomyoma along pregnancy , 2019, BMC Women's Health.

[14]  Jinhui Xu,et al.  Chromosome territories and the global regulation of the genome , 2019, Genes, chromosomes & cancer.

[15]  E. Hendrickson,et al.  Chromothripsis during telomere crisis is independent of NHEJ, and consistent with a replicative origin , 2019, Genome research.

[16]  T. Hernández-Beeftink,et al.  HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas. , 2018, Gynecologic oncology.

[17]  J. Segars,et al.  The Effect of Uterine Fibroids on Infertility: A Systematic Review , 2017, Seminars in Reproductive Medicine.

[18]  V. Baranov,et al.  Case of chromothripsis in a large solitary non-recurrent uterine leiomyoma. , 2017, European journal of obstetrics, gynecology, and reproductive biology.

[19]  V. Baranov,et al.  Differential DNA Hydroxymethylation in Human Uterine Leiomyoma Cells Depending on the Phase of Menstrual Cycle and Presence of MED12 Gene Mutations , 2017, Bulletin of Experimental Biology and Medicine.

[20]  E. Stewart,et al.  Epidemiology of uterine fibroids: a systematic review , 2017, BJOG : an international journal of obstetrics and gynaecology.

[21]  P. Vahteristo,et al.  Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors , 2017, Molecular Cancer.

[22]  T. Lange,et al.  Telomeres in cancer: tumour suppression and genome instability , 2017, Nature Reviews Molecular Cell Biology.

[23]  V. Baranov,et al.  Frequency and Spectrum of MED12 Exon 2 Mutations in Multiple Versus Solitary Uterine Leiomyomas From Russian Patients , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[24]  V. Baranov,et al.  Catechol-O-methyltransferase Val158Met polymorphism is associated with increased risk of multiple uterine leiomyomas either positive or negative for MED12 exon 2 mutations , 2016, Journal of Clinical Pathology.

[25]  J. Geigl,et al.  Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors , 2016, Modern Pathology.

[26]  F. Parazzini,et al.  Pregnancy outcome and uterine fibroids. , 2016, Best practice & research. Clinical obstetrics & gynaecology.

[27]  L. Aaltonen,et al.  MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas , 2016, British Journal of Cancer.

[28]  Qiwei Yang,et al.  Early Life Adverse Environmental Exposures Increase the Risk of Uterine Fibroid Development: Role of Epigenetic Regulation , 2016, Front. Pharmacol..

[29]  L. Wise,et al.  Epidemiology of Uterine Fibroids: From Menarche to Menopause. , 2016, Clinical obstetrics and gynecology.

[30]  V. Baranov,et al.  Comparative systems genetics view of endometriosis and uterine leiomyoma: Two sides of the same coin? , 2016, Systems biology in reproductive medicine.

[31]  L. Aaltonen,et al.  Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers , 2016, Proceedings of the National Academy of Sciences.

[32]  J. Bullerdiek,et al.  A rare coincidence of different types of driver mutations among uterine leiomyomas (UL) , 2015, Molecular Cytogenetics.

[33]  R. Moon,et al.  Wnt signaling induces transcription, spatial proximity, and translocation of fusion gene partners in human hematopoietic cells. , 2015, Blood.

[34]  Suman Lee,et al.  Epigenetic instability of imprinted genes in human cancers , 2015, Nucleic acids research.

[35]  J. Teixeira,et al.  Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. , 2015, Human reproduction update.

[36]  P. Yin,et al.  Uterine Leiomyoma Stem Cells: Linking Progesterone to Growth , 2015, Seminars in Reproductive Medicine.

[37]  F. Guyon,et al.  Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions , 2015, Modern Pathology.

[38]  Esa Pitkänen,et al.  Clonally related uterine leiomyomas are common and display branched tumor evolution. , 2015, Human molecular genetics.

[39]  J. Bullerdiek,et al.  Cytogenetically normal uterine leiomyomas without MED12-mutations – a source to identify unknown mechanisms of the development of uterine smooth muscle tumors , 2014, Molecular Cytogenetics.

[40]  Diana Magalhaes de Oliveira,et al.  The linked human imprintome v1.0: over 120 genes confirmed as imprinted impose a major review on previous censuses , 2014, Int. J. Data Min. Bioinform..

[41]  A. Clayton,et al.  Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. , 2014, American journal of obstetrics and gynecology.

[42]  Yunlang Cai,et al.  Measurement of Phenolic Environmental Estrogens in Women with Uterine Leiomyoma , 2013, PloS one.

[43]  Cameron S. Osborne,et al.  Molecular Pathways Molecular Pathways : Transcription Factories and Chromosomal Translocations , 2013 .

[44]  L. Aaltonen,et al.  Characterization of uterine leiomyomas by whole-genome sequencing. , 2013, The New England journal of medicine.

[45]  D. Baird,et al.  Gene Expression in Uterine Leiomyoma from Tumors Likely to Be Growing (from Black Women over 35) and Tumors Likely to Be Non-Growing (from White Women over 35) , 2013, PloS one.

[46]  T. Löning,et al.  MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups , 2012, International journal of cancer.

[47]  J. Harizanova,et al.  Differential positioning and close spatial proximity of translocation‐prone genes in nonmalignant B‐cells from multiple myeloma patients , 2012, Genes, chromosomes & cancer.

[48]  Tae-Min Kim,et al.  Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profilingof the t(12;14) and evidence in support of predisposing genetic heterogeneity. , 2012, Human molecular genetics.

[49]  C. Walker,et al.  Environmental Estrogens Differentially Engage the Histone Methyltransferase EZH2 to Increase Risk of Uterine Tumorigenesis , 2012, Molecular Cancer Research.

[50]  Fuqiang Huang,et al.  Hypoxia: the driving force of uterine myometrial stem cells differentiation into leiomyoma cells. , 2011, Medical hypotheses.

[51]  L. Campbell,et al.  The Role of Dicentric Chromosome Formation and Secondary Centromere Deletion in the Evolution of Myeloid Malignancy , 2011, Genetics research international.

[52]  D. Baird,et al.  Genome-wide analysis of loss of heterozygosity and copy number amplification in uterine leiomyomas using the 100K single nucleotide polymorphism array. , 2011, Experimental and molecular pathology.

[53]  P. Park,et al.  Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis , 2009, Genes, chromosomes & cancer.

[54]  J. Bullerdiek,et al.  Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease , 2009, Genes, chromosomes & cancer.

[55]  Y. Cho,et al.  Array comparative genomic hybridization analysis of uterine leiomyosarcoma. , 2005, Gynecologic oncology.

[56]  A. Sandberg Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. , 2005, Cancer genetics and cytogenetics.

[57]  P. Vercellini,et al.  Uterine fibroids and gynecologic pain symptoms in a population-based study. , 2003, Fertility and sterility.

[58]  S. Weremowicz,et al.  HMGA2 expression in uterine leiomyomata and myometrium: Quantitative analysis and tissue culture studies , 2003, Genes, chromosomes & cancer.

[59]  Tom Misteli,et al.  Spatial proximity of translocation-prone gene loci in human lymphomas , 2003, Nature Genetics.

[60]  J. Haseman,et al.  Immortalization of Human Uterine Leiomyoma and Myometrial Cell Lines After Induction of Telomerase Activity: Molecular and Phenotypic Characteristics , 2002, Laboratory Investigation.

[61]  R. Fuchs-Young,et al.  An in vivo/in vitro Model to Assess Endocrine Disrupting Activity of Xenoestrogens in Uterine Leiomyoma , 2001, Annals of the New York Academy of Sciences.

[62]  M. Sakamoto,et al.  Telomerase activity in gynecological tumors. , 2000, Oncology reports.

[63]  K. Hirschhorn,et al.  Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. , 2000, Cancer genetics and cytogenetics.

[64]  C. Morton,et al.  Genetics of uterine leiomyomata , 2000, Bulletin du cancer.

[65]  L. Giudice,et al.  Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium , 2000, International journal of cancer.

[66]  W. Jonat,et al.  Telomere shortening in uterine leiomyomas. , 1998, American journal of obstetrics and gynecology.

[67]  C. Morton,et al.  The del(7q) subgroup in uterine leiomyomata: genetic and biologic characteristics. Further evidence for the secondary nature of cytogenetic abnormalities in the pathobiology of uterine leiomyomata. , 1997, Cancer genetics and cytogenetics.

[68]  A. Berchuck,et al.  Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization , 1997, Molecular carcinogenesis.

[69]  S. Scherer,et al.  Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas , 1997, Oncogene.

[70]  P. Cin,et al.  Molecular cytogenetic characterization of del(7q) in two uterine leiomyoma‐derived cell lines , 1997, Genes, chromosomes & cancer.

[71]  J. Deprest,et al.  Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal, and gonadotropin-releasing hormone agonist-treated females. , 1996, Fertility and sterility.

[72]  K. Ohama,et al.  Detection of chromosomal abnormalities in uterine leiomyoma using conventional cytogenetic method and interphase fluorescence in situ hybridization. , 1996, Cancer genetics and cytogenetics.

[73]  K. Ohama,et al.  Detection of chromosomal abnormalities of chromosome 12 in uterine leiomyoma using fluorescence in situ hybridization , 1996, Japanese Journal of Human Genetics.

[74]  U. Surti,et al.  Molecular and cytogenetic analysis of chromosome 7 in uterine leiomyomas , 1995, Genes, chromosomes & cancer.

[75]  J. Sklar,et al.  Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata , 1994, Genes, chromosomes & cancer.

[76]  L. Meisner,et al.  Comparison of chromosome aberrations in leiomyoma and leiomyosarcoma using FISH on archival tissues. , 1994, Cancer genetics and cytogenetics.

[77]  U. Surti,et al.  Deletion 7q22 in uterine leiomyoma. A cytogenetic review. , 1993, Cancer genetics and cytogenetics.

[78]  U. Surti,et al.  Chromosome 7 biclonality in uterine leiomyoma. , 1993, Cancer genetics and cytogenetics.

[79]  F. Speleman,et al.  Uterine leiomyoma cytogenetics. III. Interphase cytogenetic analysis of karyotypically normal uterine leiomyoma excludes possibility of undetected trisomy 12. , 1992, Cancer genetics and cytogenetics.

[80]  U. Surti,et al.  Subgroups of uterine leiomyomas based on cytogenetic analysis. , 1991, Human pathology.

[81]  F. Mitelman,et al.  Chromosome analysis of 96 uterine leiomyomas. , 1991, Cancer genetics and cytogenetics.

[82]  J. Fletcher,et al.  Cytogenetic Abnormalities in Uterine Leiomyomata , 1991, Obstetrics and gynecology.

[83]  F. Mitelman,et al.  Parallel karyotypic evolution and tumor progression in uterine leiomyoma , 1990, Genes, chromosomes & cancer.

[84]  J. Fletcher,et al.  Chromosome aberrations in uterine smooth muscle tumors: potential diagnostic relevance of cytogenetic instability. , 1990, Cancer research.

[85]  S. Heim,et al.  Uterine leiomyoma cytogenetics , 1990, Genes, chromosomes & cancer.

[86]  I. Konishi,et al.  Mitotic activity in uterine leiomyomas during the menstrual cycle. , 1989, American journal of obstetrics and gynecology.

[87]  S. Gartler,et al.  Glucose-6-Phosphate Dehydrogenase Mosaicism: Utilization as a Cell Marker in the Study of Leiomyomas , 1965, Science.

[88]  T. Liehr Fluorescence In Situ Hybridization (FISH) , 2017, Springer Protocols Handbooks.

[89]  V. Baranov,et al.  Immunofluorescence Staining for Cytosine Modifications Like 5-Methylcytosine and Its Oxidative Derivatives and FISH , 2017 .

[90]  David B Dunson,et al.  High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. , 2003, American journal of obstetrics and gynecology.

[91]  C. Walker Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. , 2002, Recent progress in hormone research.

[92]  F. Mitelman,et al.  Karyotypic rearrangements in 20 uterine leiomyomas. , 1988, Cytogenetics and cell genetics.

[93]  P. Vahteristo,et al.  Characterization of MED 12 , HMGA 2 , and FH alterations reveals molecular variability in uterine smooth muscle tumors , 2022 .